316 related articles for article (PubMed ID: 30242748)
21. Long-term Management of Moderate to Severe Plaque Psoriasis Patients With Etanercept: A Case Series.
Bourcier M; Papp KA; Gulliver WP; Poulin Y; Barber K; Poulin-Costello M; Shelton J
J Cutan Med Surg; 2015; 19(6):561-9. PubMed ID: 25951825
[TBL] [Abstract][Full Text] [Related]
22. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
Gerdes S; Thaçi D; Griffiths CEM; Arenberger P; Poetzl J; Wuerth G; Afonso M; Woehling H
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):420-427. PubMed ID: 28960486
[TBL] [Abstract][Full Text] [Related]
23. Long-term (1 year) efficacy of etanercept in moderate-to-severe psoriasis. Results of a multicentric observational study in Spain.
Puig L; Camacho F; García-Patos V; Fernández-Díaz ML; Marquina A; García-Calvo C
Eur J Dermatol; 2015; 25(5):410-7. PubMed ID: 26080687
[TBL] [Abstract][Full Text] [Related]
24. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
Griffiths CEM; Thaçi D; Gerdes S; Arenberger P; Pulka G; Kingo K; Weglowska J; ; Hattebuhr N; Poetzl J; Woehling H; Wuerth G; Afonso M
Br J Dermatol; 2017 Apr; 176(4):928-938. PubMed ID: 27787890
[TBL] [Abstract][Full Text] [Related]
25. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
[TBL] [Abstract][Full Text] [Related]
26. Plasma miR-126 expression correlates with risk and severity of psoriasis and its high level at baseline predicts worse response to Tripterygium wilfordii Hook F in combination with acitretin.
Duan Y; Zou J; Mao J; Guo D; Wu M; Xu N; Zhou J; Zhang Y; Guo W; Jin W
Biomed Pharmacother; 2019 Jul; 115():108761. PubMed ID: 31100542
[TBL] [Abstract][Full Text] [Related]
27. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Lebwohl M; Blauvelt A; Paul C; Sofen H; Węgłowska J; Piguet V; Burge D; Rolleri R; Drew J; Peterson L; Augustin M
J Am Acad Dermatol; 2018 Aug; 79(2):266-276.e5. PubMed ID: 29660425
[TBL] [Abstract][Full Text] [Related]
28. Secukinumab (AIN457) for the treatment of psoriasis.
López-Ferrer A; Vilarrasa E; Puig L
Expert Rev Clin Immunol; 2015; 11(11):1177-88. PubMed ID: 26428036
[TBL] [Abstract][Full Text] [Related]
29. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
30. Ameliorative effects of a fusion protein dual targeting interleukin 17A and tumor necrosis factor α on imiquimod-induced psoriasis in mice.
Liu Z; Liu H; Xu P; Yin Q; Wang Y; Opoku YK; Yang J; Song L; Sun X; Zhang T; Yu D; Wang X; Ren G; Li D
Biomed Pharmacother; 2018 Dec; 108():1425-1434. PubMed ID: 30372845
[TBL] [Abstract][Full Text] [Related]
31. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
Bokor-Billmann T; Schäkel K
J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
[TBL] [Abstract][Full Text] [Related]
32. A randomized, 'head-to-head' pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients.
Park KK; Wu JJ; Koo J
J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):899-906. PubMed ID: 22702846
[TBL] [Abstract][Full Text] [Related]
33. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
van den Reek JMPA; Coenen MJH; van de L'Isle Arias M; Zweegers J; Rodijk-Olthuis D; Schalkwijk J; Vermeulen SH; Joosten I; van de Kerkhof PCM; Seyger MMB; Zeeuwen PLJM; de Jong EMGJ
Br J Dermatol; 2017 May; 176(5):1288-1296. PubMed ID: 27564082
[TBL] [Abstract][Full Text] [Related]
35. Etanercept treatment for children and adolescents with plaque psoriasis.
Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A;
N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of psoriasis severity and inflammatory responses under concomitant treatment with methotrexate plus micronutrients for psoriasis vulgaris: a randomized double blind trial.
Yousefzadeh H; Jabbari Azad F; Banihashemi M; Rastin M; Mahmoudi M
Acta Dermatovenerol Alp Pannonica Adriat; 2017 Mar; 26(1):3-9. PubMed ID: 28352928
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3.
Kemény L; Berggren L; Dossenbach M; Dutronc Y; Paul C
J Dermatolog Treat; 2019 Feb; 30(1):19-26. PubMed ID: 29726739
[TBL] [Abstract][Full Text] [Related]
38. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
39. Dual specificity phosphatase 22 relates to skin lesion degree and biologics history, while its longitudinal elevation during treatment reflects better outcome in psoriasis patients.
E C; Fang Y; Wu S; Meng Z; Qin G; Yang J
J Clin Lab Anal; 2022 Feb; 36(2):e24199. PubMed ID: 34973040
[TBL] [Abstract][Full Text] [Related]
40. Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies.
Griffiths CEM; Fava M; Miller AH; Russell J; Ball SG; Xu W; Acharya N; Rapaport MH
Psychother Psychosom; 2017; 86(5):260-267. PubMed ID: 28903122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]